Arthur P. DeCillis

8.5k total citations · 3 hit papers
25 papers, 5.4k citations indexed

About

Arthur P. DeCillis is a scholar working on Oncology, Genetics and Hematology. According to data from OpenAlex, Arthur P. DeCillis has authored 25 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Genetics and 8 papers in Hematology. Recurrent topics in Arthur P. DeCillis's work include Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Breast Cancer Treatment Studies (5 papers). Arthur P. DeCillis is often cited by papers focused on Chronic Lymphocytic Leukemia Research (8 papers), Chronic Myeloid Leukemia Treatments (7 papers) and Breast Cancer Treatment Studies (5 papers). Arthur P. DeCillis collaborates with scholars based in United States, Spain and Australia. Arthur P. DeCillis's co-authors include Bernard Fisher, Norman Wolmark, Richard G. Margolese, N V Dimitrov, D. Lawrence Wickerham, Anatolio B. Cruz, James L. Hoehn, E.P. Mamounas, A Brown and Edwin R. Fisher and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Arthur P. DeCillis

25 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.

1998 1.7k citations Bernard Fisher, John Bryant et al. Journal of Clinical Oncology profile →
Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.

1997 1.4k citations Bernard Fisher, A Brown et al. Journal of Clinical Oncology profile →
Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

2006 1.3k citations Moshe Talpaz, Neil P. Shah et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Arthur P. DeCillis

Since Specialization

Citations

This map shows the geographic impact of Arthur P. DeCillis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arthur P. DeCillis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arthur P. DeCillis more than expected).

Fields of papers citing papers by Arthur P. DeCillis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arthur P. DeCillis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arthur P. DeCillis. The network helps show where Arthur P. DeCillis may publish in the future.

Co-authorship network of co-authors of Arthur P. DeCillis

This figure shows the co-authorship network connecting the top 25 collaborators of Arthur P. DeCillis. A scholar is included among the top collaborators of Arthur P. DeCillis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arthur P. DeCillis. Arthur P. DeCillis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of preoperative chemotherapy on the outcome of women with operable breast cancer 2023 ·Journal of Clinical Oncology ·Bernard Fisher, John Bryant, Norman Wolmark, E.P. Mamounas, A Brown, Edwin R. Fisher, D. Lawrence Wickerham, Mirsada Begovič, Arthur P. DeCillis, (unknown), Richard G. Margolese, Anatolio B. Cruz, James L. Hoehn, Alan Lees, N V Dimitrov, Harry D. Bear	18
2	1033P First-in-human study of MALT1 inhibitor MPT-0118: Results from monotherapy dose escalation in advanced or metastatic refractory solid tumors 2023 ·Annals of Oncology ·Aung Naing, (unknown), Samuel J. Klempner, Sabbir Khan, Paul G. Pearson, Joelle Lufkin, Peter M. Keller, Hagop Youssoufian, Arthur P. DeCillis, Irina B. Mazo, David Sommerhalder	2
3	CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors. 2023 ·Journal of Clinical Oncology ·(unknown), Navid Hafez, Anthony W. Tolcher, Patricia LoRusso, Sharon Wilks, Debu Tripathy, (unknown), Paul G. Pearson, Arthur P. DeCillis, Funda Meric‐Bernstam	4
4	485 Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors 2021 ·SHILAP Revista de lepidopterología ·Maura L. Gillison, Mark M. Awad, Przemyslaw Twardowski, Ammar Sukari, Melissa L. Johnson, Rudy P. Lackner, Mark N. Stein, Arthur P. DeCillis, Richard Hernandez, (unknown), (unknown), Mara G. Shainheit, (unknown), (unknown), (unknown), (unknown), Emily Tjon, Jessica B. Flechtner, Thomas A. Davis, Roger B. Cohen	1
5	A Phase 1/2 Study of Quizartinib (Q) in Combination with Re-Induction Chemotherapy and As Single-Agent Continuation Therapy in Pediatric and Young Adult Patients with Relapsed/Refractory (R/R) FLT3-ITD Acute Myeloid Leukemia (AML) 2019 ·Blood ·C. Michel Zwaan, E. Anders Kolb, (unknown), (unknown), (unknown), (unknown), Arthur P. DeCillis, Cara A. Rabik, Todd M. Cooper	1
6	A phase I trial of GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumour mutations 2019 ·Annals of Oncology ·P. Twardowski, Melissa L. Johnson, Mark N. Stein, Ulka N. Vaishampayan, Maura L. Gillison, Lisa K. McNeil, Louisa Dowal, Daniel B. DeOliveira, Maneesh Jain, (unknown), Richard Hernandez, Arthur P. DeCillis, Navneet Singh, Thomas A. Davis, Jessica B. Flechtner, Rachel Cohen	2
7	Molecular Profile and Anti-Tumor Activity in Non-Small Cell Lung Cancer (NSCLC) Patients (PTS) in a Phase 1 Study of Cabozantinib (XL184) in Japan 2012 ·Annals of Oncology ·Hiroshi Nokihara, Nobuyuki Yamamoto, Shinji Nakamichi, Hiroshi Wakui, Yuichi Yamada, John Frye, Arthur P. DeCillis, Tetsuo Tamura	2
8	P1-17-02: A Phase 1/2 Study of SAR245408 (S08) in Combination with Trastuzumab (T) or Paclitaxel (P) and T in Patients with HER2+ Metastatic Breast Cancer (MBC) Who Progressed on a Previous T-Based Regimen. 2011 ·Cancer Research ·SM Tolaney, Howard A. Burris, Elaina M. Gartner, IA Mayer, Cristina Saura, Matthew J. Maurer, Arthur P. DeCillis, Rodrigo Ruiz‐Soto, Joanne Lager, EP Winer, Ian E. Krop	1
9	Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma 2011 ·Blood ·Jennifer R. Brown, Matthew S. Davids, Jordi Rodón, Pau Abrisqueta, Arthur P. DeCillis, Kevin Rockich, Coumaran Égile, (unknown), Yi Xu, Joanne Lager, Farrukh T. Awan	10
10	A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors 2008 ·Journal of Clinical Oncology ·Kyriakos P. Papadopoulos, B. Markman, Josep Tabernero, Akash Patnaik, Elisabeth I. Heath, Arthur P. DeCillis, Douglas Laird, Sunil Aggarwal, L.N. Nguyen, Patricia LoRusso	20
11	Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias breakdown → 2006 ·New England Journal of Medicine ·Moshe Talpaz, Neil P. Shah, Hagop M. Kantarjian, Nicholas J. Donato, John Nicoll, Ron Paquette, Jörge E. Cortes, Susan O’Brien, Claude Nicaise, Eric Bleickardt, (unknown), Vishwanath R. Iyer, Tai‐Tsang Chen, Fei Huang, Arthur P. DeCillis, Charles L. Sawyers	1288
12	A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant chronic phase chronic myeloid leukemia (CML): Results from CA180002 2005 ·Journal of Clinical Oncology ·Moshe Talpaz, Hagop M. Kantarjian, Ron Paquette, Neil P. Shah, Jörge E. Cortes, John Nicoll, S A Bai, Fei Huang, Arthur P. DeCillis, Charles L. Sawyers	27
13	A phase I study of BMS-354825 in patients with imatinib-resistant and intolerant accelerated and blast phase chronic myeloid leukemia (CML): Results from CA180002 2005 ·Journal of Clinical Oncology ·Charles L. Sawyers, Neha Shah, Hagop M. Kantarjian, Jörge E. Cortes, Ron Paquette, John Nicoll, S A Bai, Edwin Clark, Arthur P. DeCillis, Moshe Talpaz	26
14	Hematologic and Cytogenetic Responses in Imatinib-Resistant Chronic Phase Chronic Myeloid Leukemia Patients Treated with the Dual SRC/ABL Kinase Inhibitor BMS-354825: Results from a Phase I Dose Escalation Study. 2004 ·Blood ·Charles L. Sawyers, Neil P. Shah, Hagop M. Kantarjian, Nicholas J. Donato, John Nicoll, Stephen A. Bai, Fei Huang, Edwin Clark, Arthur P. DeCillis, Moshe Talpaz	42
15	Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies 2004 ·Clinical Cancer Research ·Quincy Chu, Lisa A. Hammond, Garry Schwartz, Leonel Ochoa, Sun Young Rha, Louis Denis, (unknown), (unknown), Stephen P. Letrent, Bharat Damle, Arthur P. DeCillis, Eric K. Rowinsky	43
16	Acute Myeloid Leukemia and Myelodysplastic Syndrome After Doxorubicin-Cyclophosphamide Adjuvant Therapy for Operable Breast Cancer: The National Surgical Adjuvant Breast and Bowel Project Experience 2003 ·Journal of Clinical Oncology ·Roy E. Smith, John Bryant, Arthur P. DeCillis, Stewart Anderson	227
17	Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. 2002 ·PubMed ·Steven J. Cohen, Cynthia G. Leichman, (unknown), Mary Beard, (unknown), (unknown), Bharat Damle, Stephen P. Letrent, Arthur P. DeCillis, Neal J. Meropol	37
18	Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. breakdown → 1998 ·Journal of Clinical Oncology ·Bernard Fisher, John Bryant, Norman Wolmark, E.P. Mamounas, A Brown, Edwin R. Fisher, D. Lawrence Wickerham, Mirsada Begovič, Arthur P. DeCillis, A. Robidoux, Richard G. Margolese, Anatolio B. Cruz, James L. Hoehn, Alan Lees, N V Dimitrov, Harry D. Bear	1688
19	Tamoxifen and Chemotherapy for Lymph Node-Negative, Estrogen Receptor-Positive Breast Cancer 1997 ·JNCI Journal of the National Cancer Institute ·Bernard Fisher, James J. Dignam, Birol Emir, John Bryant, Arthur P. DeCillis, Norman Wolmark, D. L. Wickerham, N V Dimitrov, Neil Abramson, J. N. Atkins, Henry R. Shibata, L Deschênes, Richard G. Margolese	366
20	Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. breakdown → 1997 ·Journal of Clinical Oncology ·Bernard Fisher, A Brown, E.P. Mamounas, (unknown), A. Robidoux, Richard G. Margolese, Anatolio B. Cruz, Edwin R. Fisher, D. Lawrence Wickerham, Norman Wolmark, Arthur P. DeCillis, James L. Hoehn, Alan Lees, N V Dimitrov	1373

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact